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Abstract
Human cytomegalovirus (CMV) infection is a substantial cause of morbidity and mortality in
immunocompromised hosts and globally is one of the most important congenital infections.
The nucleoside analogue ganciclovir (GCV), which requires initial phosphorylation by the
viral UL97 kinase, is the mainstay for treatment. To date, CMV decay kinetics during GCV
therapy have not been extensively investigated and its clinical implications not fully appreci-
ated. We measured CMV DNA levels in the blood of 92 solid organ transplant recipients with
CMV disease over the initial 21 days of ganciclovir therapy and identified four distinct decay
patterns, including a new pattern exhibiting a transient viral rebound (Hump) following initial
decline. Since current viral dynamics models were unable to account for this Hump profile,
we developed a novel multi-level model, which includes the intracellular role of UL97 in the
continued activation of ganciclovir, that successfully described all the decline patterns
observed. Fitting the data allowed us to estimate ganciclovir effectiveness in vivo (mean
92%), infected cell half-life (mean 0.7 days), and other viral dynamics parameters that deter-
mine which of the four kinetic patterns will ensue. An important clinical implication of our
results is that the virological efficacy of GCV operates over a broad dose range. The model
also raises the possibility that GCV can drive replication to a new lower steady state but ulti-
mately cannot fully eradicate it. This model is likely to be generalizable to other anti-CMV
nucleoside analogs that require activation by viral enzymes such as UL97 or its
homologues.
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Author summary
Cytomegalovirus (CMV) remains a cause of disease in individuals with weakened
immune systems such as patients undergoing organ transplantation. The mainstay of
treatment for CMV is ganciclovir: a CMV-specific drug that looks like a building block of
the viral DNA and which requires activation by a protein contained within CMV. Under-
standing how patients respond to treatment can lead to a better understanding of the
basic biology of CMV in the human and also help to optimize treatment regimens. In this
study we observed that following treatment of CMV disease in organ transplant patients,
CMV viral loads decay according to four distinct patterns. We have developed a novel
mathematical model that is able to describe each of these decay patterns. The model could
potentially be used to assess how different patients respond to treatment in clinical set-
tings and also to design better drug regimens as per patient. These results have striking
implications in terms of how long patients should remain on treatment and provide new
insight into CMV infection in the human host.
Introduction
Human cytomegalovirus (CMV), a member of the beta herpesvirus sub-family, has co-evolved
with humans over many millennia and usually does not cause disease in the immunocompe-
tent host [1,2]. However, in a variety of immune deficient/immature hosts including the neo-
nate, organ transplant recipients, patients with common variable immune deficiency (CVID)
and Human Immunodeficiency Virus (HIV)-infected patients, the virus can cause life-threat-
ening pathologies [3,4]. Thus, CMV has a significant economic impact on general healthcare
costs, especially in the transplant setting [5]. Despite recent encouraging results, there is no
licensed vaccine against CMV[6–8]. Consequently, antiviral chemotherapy using ganciclovir
(GCV) or its valine ester valganciclovir (VGCV) is currently the major clinical management
tool. The drug can be given prophylactically, pre-emptively or for therapy of overt CMV syn-
drome and disease [9] although questions related to dosing and duration of treatment remain
open [10,11].
Ganciclovir (GCV) belongs to a family of acyclic nucleoside analogues that includes aciclo-
vir/valaciclovir (used for the clinical management of alpha herpesvirus infections such as Her-
pes Simplex Virus (HSV) and Varicella Zoster Virus (VZV)), which require a viral kinase
(UL97 for CMV and thymidine kinase for HSV and VZV) for their initial phosphorylation
step en route to the biologically active triphosphate form of the drug [12–15]. This mode of
drug activation is important for the selectivity of the drug in infected cells but may also poten-
tially result in a complex interplay between virus inhibition and drug effectiveness. Thus,
understanding the interaction between CMV, expression of UL97 and GCV phosphorylation
may have broader implications for herpesvirus treatment in general.
Mathematical models of viral dynamics [16] have been of immense use for our understand-
ing of virus-drug interactions and optimization of therapy, particularly in HIV [17,18], Hepati-
tis C Virus (HCV) [19–22] and Hepatitis B Virus (HBV) [23,24]. However, with the exception
of basic analyses of CMV kinetics during therapy [25–28], no detailed mathematical model of
the dynamics of CMV, or other herpes viruses, is currently available. Consequently, we have
utilized frequent viral load measurements over the first 21 days of therapy with GCV in solid
organ transplant patients with CMV disease (the “VICTOR” trial [29]) to develop a compre-
hensive model of CMV dynamics that reveals the unique interplay between virus replication,
drug activation and control of replication.
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Results
Post-therapy CMV kinetic patterns
Analysis of individual viral kinetic patterns in 92 patients from the VICTOR study [29] with
single CMV genotype infection (see methods for full patient information) revealed a number
of kinetic patterns with distinct phases during the first month of treatment (Fig 1). In the first
phase (days 0–3) most, but not all, patients showed a rapid decline in viral load. Following this
decline was an intermediate phase (days 3–7 or 3–14), in which in some of the patients’ viral
loads continued to decline (albeit slower), but a large fraction of patients exhibited a shoulder
or transient rebound (Hump) in viral load. Lastly, almost all patients had a slow decline in
CMV load on days 7–21 or 14–21. Consequently, we were able to classify all patients into 4 dis-
tinct viral kinetic patterns (see Fig 1 and Table 1; the full definition of the classification criteria
is given in the methods section): Biphasic (BP, 21% of patients) where a rapid first phase
decline (days 0–3) was followed by a slower second phase decline (days 3–21); Hump (HM,
60%) where an intermediate shoulder or transient rebound was observed (days 3–7, 7–14 or
3–14) between the first and second decline phases; Delay (DL, 15%) where a slow first phase
decline occurred (days 0–3 or 0–7) followed by a slow, albeit faster than the first phase, second
phase decline; Rebound (RB, 4%) where a rapid first phase decline was followed by a rebound
between days 7–21.
Such a diverse kinetic response of the same virus to the same therapy has not been observed
for other viruses such as HIV and HCV. In particular, the HM pattern with a transient
rebound, but nevertheless a good endpoint response, is a unique pattern not observed before in
patients with consistent drug exposure. Interestingly, the mean baseline CMV load in the DL
profile was significantly (p<0.001) lower than in the HM and BP profiles, while the baseline
viral load in the RB group was not significantly higher (p<0.02) (Table 1 and Fig 1). The first
phase decline in viral load was comparable in the BP, HM and RB groups and by definition
lower in the DL patients. The second phase decline was similar in the BP, HM and DL groups.
The endpoint viral loads for the HM, BP and DL profiles were similar, but not significantly
higher for the RB profile as compared to the HM, BP and DL profiles (p<0.008). Moreover, we
observed correlations between the baseline viral loads and the endpoint viral loads in the HM
profile (R = 0.64, p<0.001), the BP profile (R = 0.74, p<0.001) and the DL profile (R = 0.63;
p = 0.016), and between second phase decline and total magnitude of the viral load decline in
the HM, BP and DL groups (R = 0.79, p<0.001; R = 0.82, p<0.001; R = 0.71, p = 0.004; respec-
tively). Interestingly, we saw a trend for difference in the pattern distribution between the vari-
ous CMV genotypes (Table 2), with the HM pattern more frequently observed in patients with
genotype gB1 infection (69% of gB1 have HM) compared to the other genotypes (52%).
Validation of the CMV kinetic pattern classification
In order to validate our classification system, we further analyzed 89 patients with a mixed
CMV genotype infection. We focused on analyzing the kinetics of the CMV gB1 genotype (the
most common and most dominant genotype in our data set), which was available for 72
patients. Using the same set of classification criteria developed in the initial study, we were
able to classify the viral kinetic pattern in 94% of the patients (in 4 patients the classification
was not conclusive due to missing data). The HM pattern was found in 49% of the gB1 profiles
in mixed-genotype infected patients, while 31% had a BP profile, 10% a DL profile and 6% a
RB profile. Thus, these results validate the robustness of the classification criteria we developed
previously and also show a distribution of kinetic profiles very similar to that found in the
patients infected with single gB genotype infections. Interestingly, different genotypes within
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the same patient exhibited different kinetic patterns in 51% of the patients. We did not proceed
with a full classification of the different genotypes in all patients since there are 11 different
combinations of genotypes (2–4 genotypes per patient) making the sub-sets too small for a
robust analysis.
Fig 1. Different kinetic patterns of viral decay observed after the initiation of ganciclovir therapy (Hump (HM; panel A), Biphasic (BP; panel
B), Delay (DL; panel C) and Rebound (RB; panel D). Data are shown for the mean (in black) and for four randomly-selected patients per profile (red,
purple, blue and green connected points) illustrating the four profiles.
https://doi.org/10.1371/journal.ppat.1006299.g001
CMV dynamics
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Modeling CMV viral dynamics
The standard model of viral dynamics (Fig 2a) used for analyzing HIV, HCV and HBV kinet-
ics [16,19,23] yields a biphasic viral decline pattern if the drug is assumed to block viral pro-
duction and/or secretion, or a monophasic decline if the drug is assumed to block de-novo
infection. However, it cannot fit the complete data set observed here with four distinct viral
decline patterns, and in particular, it is unable to model the HM pattern observed for the
majority of the patients. The only way to force the standard model to give rise to a transient
rebound is through a pharmacokinetic effect where drug levels are assumed to decrease at day
3 and then increase again at day 7. However, this is very unlikely in this clinical study since all
patients received equal doses of drug twice a day (adjusted for renal function to maintain drug
levels) throughout the 21 days of full dose medication [29,30]. Moreover, we had analyzed data
for GCV dose and drug levels in the blood that were available for a subset of the patients and
had not found any indication for such changes in drug levels that would account for the HM
pattern. The inclusion of a transitory change in the immune response could give rise to a
shoulder phase [31], if one assumes that a weaker immune response is occurring at the initia-
tion of therapy followed by a stronger immune response after a few days or weeks of therapy.
However, such a model based on changes in the immune response (affecting the loss of
infected cells and or viral clearance) cannot give rise to a transitory rebound (Hump) as
observed here in the majority of the patients. Evolution of resistance could explain the RB pat-
tern but not the HM pattern, but we have verified that the HM and RB patterns were not
Table 1. Summary of CMV kinetic properties per kinetic pattern group.
Viral Kinetic (VK) Property Viral Kinetic Pattern
(mean± StDev) Hump (HM) Biphasic (BP) Delayed (DL) Rebound (RB)
Patients per VK pattern (%) 55 (60%) 19 (21%) 14 (15%) 4 (4%)
Baseline CMV load (log ge/ml) 5.2 ± 0.7 5.3 ± 0.9 4.3 ± 0.6 *1 6.1 ± 0.5 *2
1st phase slope (log ge/ml/week) -3.2 ± 0.2 -2.3 ± 0.1 -0.5 ± 0.1 -3.5 ± 0.1
1st phase decline magnitude (log ge/ml) -1.4 ± 0.5 -1.0 ± 0.3 -0.2 ± 0.2 *3 -1.5 ± 0.3
Hump magnitude (log ge/ml) +0.2 ±0.2 *4 -0.3 ± 0.2 -0.3 ± 0.4 -0.8 ± 0.4
2nd phase slope (log ge/ml /week -0.8 ± 0.1 -0.7 ± 0.1 -0.5 ± 0.1 +0.3 ± 0.1 *5
Endpoint CMV load (log ge/ml) 2.8 ± 0.8 2.6 ± 0.8 2.7 ± 0.8 4.4 ± 0.1 *6
*1) Baseline CMV load in patients with DL is significantly (p<0.001) lower than that of HM, BP and RB.
*2) Baseline CMV load in patients with RB is higher (p<0.02) than that of HM, BP and DL.
*3) 1st phase decline in patients with DL is significantly (p<0.001) lower than that of HM, BP and RB (by definition).
*4) Slope at days 3–7 in patients with HM is significantly (p<0.001) different than that of BP and DL (by definition).
*5) 2nd phase slope at days 7–21 in patients with RB is significantly (p<0.001) different than that of HM, BP and DL (by definition).
*6) Total CMV magnitude of decline at day 21 in patients with RB is higher (p = 0.008) than that of HM, BP and DL.
https://doi.org/10.1371/journal.ppat.1006299.t001
Table 2. Distribution of the viral kinetics patterns per CMV genotype.
Genotype N (% of profile/genotype HM BP DL RB
gB1 42 (46%) 29 (69.0%) 6 (14.3%) 7 (16.7%) 0 (0.0%)
gB2 16 (17%) 7 (48.3%) 6 (37.5%) 2 (12.5%) 1 (6.3%)
gB3 22 (24%) 13 (59.1%) 4 (18.2%) 3 (13.6%) 2 (9.1%)
gB4 12 (13%) 6 (50.0%) 3 (25.0%) 2 (16.7%) 1 (8.3%)
All 92 55 19 14 4
https://doi.org/10.1371/journal.ppat.1006299.t002
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associated with genotypic resistance to GCV (UL97 or UL54) since these patients were
excluded from this analysis [32]. A number of other modifications to the standard model were
tested including using a number of different infected cell populations, physiological compart-
ments and intracellular compartments. However, none of these modifications to the model
reproduced the complete set of observations, including the HM and DL patterns and the corre-
lations mentioned above.
Thus, we developed a novel mathematical model that specifically incorporates the intracel-
lular dynamics of the interaction between CMV and GCV (Fig 2b; see full description of the
ordinary differential equation (ODE) set of equations in the methods section). A characteristic
of GCV is its dependence on the UL97 viral kinase (U), transcribed from viral DNA (D1) and
produced as an early/late protein whose synthesis depends on viral DNA replication, in order
to be intracellularly phosphorylated from its nucleoside form (G0) en route to its tri-phosphate
active form (G3). In the model, viral DNA (D1) replication is inhibited by the activated GCV
form of ganciclovir (G3) with effectiveness epsilon (ε). The decline in DNA levels leads to a
reduction in UL97 levels and accordingly, less GCV activation. As a consequence, DNA repli-
cation increases again, producing more UL97, activating more GCV, and again inhibiting
DNA replication. This cycle continues until a new equilibrium, with lower CMV DNA levels
than baseline, is reached between CMV DNA replication, UL97 levels and GCV activation. By
incorporating these intracellular dynamics into the infected cells variable (I) in the standard
viral kinetics model, where part of the CMV DNA (D1) is assembled into virions (D2) and
exported into circulation, we obtain a specific CMV-GCV viral dynamics model. Although a
small amount of GCV mono-phosphorylation occurs in the absence of UL97, we have
assumed this leads to a low level of activated drug compared to a CMV infected cell and is con-
sistent across all patients.
Fig 2. Panel A: The basic viral dynamics model, in which therapy blocks the production of virus, yields a biphasic viral decline pattern, but is not able to
reproduce the complete set of kinetic patterns observed here for the effect of ganciclovir on CMV. Panel B: The novel viral dynamics model developed
here for ganciclovir’s effect on CMV replication. In this model the intracellular negative feedback loop between UL97 and ganciclovir is explicitly modeled.
Variable key (full description in the Methods section): T = target cells, I = infected cells, V = free virus, U = intracellular UL97 enzyme concentration, Go =
intracellular ganciclovir concentration, G3 = intracellular concentration of the active tri-phosphorylated form of ganciclovir, D1 = intracellular linear/circular/
concatemeric forms of viral DNA, D2 = intracellular cleaved/packaged viral DNA, WB = whole blood viral load, ε = drug efficacy.
https://doi.org/10.1371/journal.ppat.1006299.g002
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Strikingly, this new model was able to account for all the viral kinetic patterns observed in
the data (Fig 3, and see simulation of the kinetics of more variables of the model in S1 Fig).
When the intracellular dynamics are slow, the GCV-CMV interaction has no significant
impact on the blocking effectiveness of GCV, which remains approximately constant
Fig 3. Fitting of the new GCV-CMV model to the viral decline data observed after the initiation of ganciclovir therapy per the four kinetic
profiles (Hump (HM; panel A), Biphasic (BP; panel B), Delay (DL; panel C) and Rebound (RB; panel D). Data are shown for four single randomly-
selected patients (red, purple, blue and green connected data points) illustrating the four profiles in tandem. The means per profile are shown in black.
https://doi.org/10.1371/journal.ppat.1006299.g003
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throughout therapy and hence viral decline is biphasic (BP pattern) as in the standard model.
The magnitude of the first phase depicts the blocking effectiveness (ε) and the second phase
decline slope is related to the loss rate of infected cells. However, when the dynamics of intra-
cellular DNA, UL97 and activated GCV is fast, the blocking effectiveness is more sensitive to
changes in GCV levels (Fig 3), consequently oscillations occur in the blocking effectiveness
and viral DNA levels rebound more rapidly intracellularly. When this is combined with the
decline of infected cells, a transient rebound in the whole blood viral load manifests (HM pat-
tern). If the decline in infected cells is slow (a small δ) then a longer and more pronounced
rebound is observed in the whole blood viral load time series curve (RB pattern). On the other
hand, if both intracellular dynamics and intracellular DNA replication rates are slower, then
UL97 levels are lower and GCV activation is reduced, with a slower effect on DNA levels, and
the ensuing whole blood viral load decline is delayed (DL pattern).
How the model explains the different CMV kinetic patterns
Of specific interest is the understanding of the differences in the model parameter values that
yield each kinetic profile pattern. We found that ε was 8% lower on day 7 than it was on day 3
and we did not observe this difference in the other categories. This is further strong evidence
that the hump occurs due to the decrease in the amount of phosphorylated GCV: the lack of
available active drug resulting in a decrease in viral blocking and a subsequent increase in cell-
associated viral load. We also observed a subsequent increase in ε by day 14 in the HM cate-
gory: the value continues to decline in all other categories following day 7. We also found this
pattern in G3: there was 68% less ganciclovir triphosphate (GCVTP; G3) on day 7 than on day
3 in the HM profile, and 8% more on day 14 than on day 7. This modulation in GCVTP levels
does not occur in any other group. D1 and D2 decline rapidly due to the effects of ε and subse-
quently transiently increase on or around day 3 in the HM profile until both reach a new
steady state.
The only qualitative or quantitative differences between the HM and BP profiles are the
slopes between days 3 and 7 and the 1st slope. Furthermore, since the viral load at day 0 (VL0),
the endpoint viral load (VL21) and 2nd slopes are almost identical between the HM and BP
profiles, (Table 1) we used these two profiles as a comparative means to reveal the exact differ-
ences in parameters that yield these particular profiles. If our hypothesis is correct, then the
difference in profiles should be inducible by simply modifying the intracellular parameter val-
ues associated with U and G3. The value for du, the decay rate for UL97 (U), is highly influential
with respect to the feedback loop between U and G3 and in fact, by simply modifying this and
one other parameter associated with treatment efficacy (ε), the HM profile can be generated.
Indeed ε is the effectiveness of the drug at blocking viral replication and in our model; ε is a
dynamical variable and is a function of time. This is the strength of our model: ε depends on
the negative feedback loop between the drug and UL97 and thus depending on the particular
feedback, the model is capable of simulating different viral kinetic patterns. In order to exam-
ine modifications of ε, we need to change the parameters that affect ε. The Hill parameter, h, is
one of these parameters and represents the steepness of the Hill saturation function and
defines the sensitivity of the blocking effectiveness to changes in drug level via cooperativity of
drug binding. In addition to h, θ and G3 also affect ε where θ represents the apparent dissocia-
tion constant derived from the law of mass action and G3 is the ligand and is related to drug
dose rather than blocking efficacy.
Interestingly, the value of du in the HM profile is higher than for the other profiles, which
means that UL97 is cleared from the system more rapidly and thus less available for phosphor-
ylating G0. This would set the stage for higher viral loads in the context of high treatment
CMV dynamics
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efficacy and perhaps temporarily offsets the ‘decay balance’ of the system inducing a transient
rise in viral load. The value of the du parameter is almost completely responsible for the HM
profile. The parameter du was found to be statistically-significantly different between the HM
and BP profiles (p<0.001). Another parameter that differs between the HM and BP profiles is
the Hill parameter, h, whose value partially determines the efficacy of ε. The value of h in fact
dictates a change in the profile pattern. The parameter h was found to be significantly higher
in the HM profile as compared to the BP profile (p<0.001). Ultimately, the inter-relationship
between du and the treatment parameter can wholly define the HM, BP and RB kinetic profile
patterns in viral load as seen by fitting their decline data (Fig 3). Interestingly, this is not case
for the DL profile. Fits of individual patient data revealed that all individuals could be defined
per profile exclusively by modifying h and du except for individuals with DL profile. These indi-
vidual fits required more precision.
We used a parameter-fit scenario that corresponded to our biological assumptions and
found that when we allowed the modification of three additional parameters: ρ1, ρ2 and δ, we
could fit each patient using the model. The parameter ρ1 is the rate at which U enters the sys-
tem (the conversion rate from D1 to D2) and ρ2 is dependent on ρ1 (the conversion rate from
D2 to V) and thus both, like du, are influential with respect to the feedback loop between U and
G3. Specifically, these parameters have a very pronounced impact on the 1st slope. The loss rate
of infected cells δ, albeit not influential in the feedback loop, is highly influential with respect
to the 2nd slope thus relevant to achieve individual fit precision, especially for the DL and RB
profiles.
A complete analysis of the distribution of these 5 parameters for all patients showed a
multi-modal distribution as a function of the four kinetic profiles, as shown in Supplementary
Figure 2 (S2 Fig). Taking into account the differences in the numbers of patients per profile,
we found that ρ1 was significantly different between the DL profile and all the HM, BP and RB
profiles (p<0.001, p<0.001, p = 0.002; respectively). We also found no significant difference in
ρ1 between the BP and RB profiles. ρ2 was significantly different between the DL profile and
the HM, BP and RB profiles (p<0.001, p<0.001, p<0.001; respectively). The parameter δ was
found to be significantly different between the RB profile and the HM and BP profiles
(p<0.001, p<0.001; respectively) and between the BP and the HM, DL and RB profiles
(p = 0.01, p<0.001, p<0.001, respectively). Lastly, du was found to be significantly different in
the HM profile from the BP, DL and RB profiles (p<0.001, p<0.001, p<0.001; respectively).
Furthermore, the values for these five parameters were not dependent on other patient or virus
related co-factors. There were no significant differences in the distributions of these five
parameters as function of the four CMV gB genotypes.
As part of our mathematical simulations we assessed the effects of changing the value of the
decay rate for UL97 (du). When we increased the value of du, we saw the total amount of WB
virus rise and the shape of the trajectory change until eventually there was barely a hump. This
is because there was less U for consumption, and therefore less G3 and a lower value for ε.
Thus, we observed an increase in D1, D2 and V. When we decreased its value, we saw the viral
load decay more rapidly and the shape of the trajectory change until again, there was no appre-
ciable hump.
Upon further examination, we noticed that the RB profile closely resembled the HM profile,
albeit temporally delayed. We used the model to project the behavior of the WB viral load
beyond day 21 and noticed that at day 21 the viral load in the RB profile began to decline
anew. By day 90, the viral load was undetectable. Consistent with this explanation was the find-
ing that while plasma CMV loads at day 21 were detectable (>600 genomes/ml) in 100% of RB
patients it fell to 25% of RB patients by day 49. We assessed post-primary endpoint data in
plasma samples for the VICTOR study patients and noted that the viral load continued to
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decline to undetectable levels (2.77 log genomes/ml by day 49). This has significant clinical
implications in that these patients should not discontinue treatment in the face of increasing
viral loads at day 21 as might be advised by a health care practitioner but instead, stay on treat-
ment as eventually, the viral load will decline even to undetectable levels in some patients. This
provides confirmation that the viral load will continue to decline after day 21 in all patients
manifesting the RB profile.
Dose-dependent viral kinetics
Lastly, we investigated what effects, if any, a lower or higher treatment dose would have on the
trajectories for each kinetic profile. G0 represents the dose of the drug and its value also par-
tially determines the efficacy of ε. Thus, in order to appropriately model a dose change, rather
than viral/host properties (how the drug affects blocking), we used modifications in G0 to
mimic a change in drug dose. We modified the level of G0 to model drug efficacies that
equated to ε at 80%, 90% and 95% for each profile (S3 Fig). According to the simulated HM,
BP and RB kinetic patterns, a higher dose (in relation to the dose that yields the mean data)
leads to a more substantial reduction in the nadir of the first phase decline. In the case of the
HM and BP patterns, increasing the dose also results in a moderately faster second phase
decline meaning that both phases are sensitive to drug dose but the first phase is far more sen-
sitive. The DL pattern shows a dose-dependent difference in decline rates whereby the slope of
the decay trajectory is progressively steeper for higher doses.
An important observation for the patients with the RB profile is that, according to the
model simulations (S3 Fig), the WB ceases to increase post day 21 and actually starts to decline.
Thus, according to this prediction, in a clinical setting it might be advisable for patients with
the RB profile to continue treatment post day 21 in spite of the fact that it appears as though
the viral load is increasing. This prediction is corroborated by the observation of low plasma
viral load measurements in the VICTOR trial for the RB patients at day 49 and 84 [29].
Discussion
Understanding CMV replication in the human host and identifying predictors for the
response to therapy remains important for the clinical management of this infection in the
immunocompromised host. Until now, our understanding of CMV kinetics following therapy
has been limited to deploying basic models of viral dynamics. The availability of datasets from
large clinical trials of antiviral medication with frequent (in particular measurement as early as
day 3 of treatment) and precise (using an assay with less than 0.15 log variability) with viral
load measurements is invaluable to determine viral kinetics during therapy. Using data from a
clinical trial [29] comparing intravenous GCV with a valine ester pro-drug of GCV [3], we
were able to both identify and validate, in 2 separate groups of patients, four distinct kinetic
patterns of CMV decline during the first 21 days of therapy. While two profile patterns had
been previously observed (Biphasic and Delay) [25,27,32], two new profile patterns (Hump
and Rebound) were observed. The Hump (HM) profile, characterized by a rapid decline in
viral load followed by a transient increase and a subsequent second phase decline, occurred in
a significant proportion of the patients and was unexpected. Re-evaluation of other CMV viral
load decline data from previous studies [25] indeed clearly indicates the presence of a Hump
profile in some patients.
Since conventional viral dynamic models were unable to account for the four patterns
observed following therapy with GCV, particularly the Hump pattern, we turned our attention
to the biology of CMV-induced drug activation of GCV as a means to develop a novel multi-
level model which explicitly incorporated the intracellular interplay between UL97 levels,
CMV dynamics
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006299 April 13, 2017 10 / 19
phosphorylated anti-virally active GCV triphosphate and levels of intracellular CMV DNA.
This new viral dynamic model for GCV-CMV interaction was able to account for all four
kinetic patterns observed in-vivo, including the Hump profile. Although UL97 is present in
the virion in small amounts, the model implies that this UL97 does not play a major role in the
activation of GCV but rather plays a role in the other functions of UL97.
Our model implies that drugs such as GCV that require viral enzymes (such as UL97) for
activation cannot, by themselves, eliminate viral replication from an infected cell population,
arguing that an effective cell-mediated immune response is also a critical component of clear-
ance. This has relevance in the context of recurrence of DNAemia following prophylaxis
where high-risk patients who developed a T-cell response against CMV were less likely to
experience late CMV infection [33] and in transplant patients treated pre-emptively where sec-
ond episodes of replication are common [34].
Using model simulations, the key parameters that change one kinetic profile into another
were identified as the loss rate of infected cells (δ) together with the parameters governing the
intra-cellular feedback loop between UL97 dynamics (du), DNA replication (ρ1, and ρ2) and
the GCV blocking effectiveness function (h). This provides further evidence that the success of
anti-herpesvirus treatment with drugs that require activation via viral proteins such as UL97
involves a complex interplay between viral replication, transcription and production of the
active kinase and appropriate intracellular levels of active drug. The HM pattern that we have
observed at high frequency for CMV during GCV therapy would be expected to occur with
other antiviral drugs that require UL97 for activation such as valaciclovir and cyclopropavir
[35]. Their efficacy at eliminating viral replication could be determined depending whether
the HM pattern is observed clinically for these drugs. Studies involving patients taking anti-
CMV drugs would also provide a test of our model.
Of particular interest in this work is the effect of drug dose on the viral kinetics. From our
simulations, the dose of ganciclovir appears to only have a modest long-term influence on
patients exhibiting the Hump (HM), Biphasic (BP) or Rebound (RB) kinetic pattern. Patients
with a Delay (DL) kinetic pattern may benefit from a higher dose by exhibiting a larger decline
in viral load by day 21, but unfortunately, for the majority of these patients, an undetectable
viral load is hard to achieve even with higher doses. For drugs that do not require activation
through a viral kinase such as the lipid ester of cidofovir (CMX001) [36] and the terminase
inhibitor AIC246 (Letermovir) [37], the kinetic patterns post-therapy are likely to be predomi-
nately biphasic and not limited by the UL97 negative feedback loop. Therefore, we predict that
drug efficacy will make a marked difference in time to PCR-negative status with these other
drugs and thus appropriate viral kinetics based dose-ranging phase 2 studies are needed to
optimize these other drugs. Such an approach would have been valuable in the context of Mar-
ibavir [38].
Of clinical relevance are the Delay and Rebound patterns. Other studies have shown that
viral loads after the initiation of GCV therapy can remain static or even increase for a time
after initiation of therapy [39,40] and in one study this has been shown to be associated with
rapid replication kinetics prior to therapy [41]. In our analysis, patients with the Delay pattern
tended to have lower baseline viral loads, possibly indicating that these patients had intrinsi-
cally low CMV replication rates giving rise to low availability of UL97, thus limiting the quan-
tity of intracellular active GCV and giving rise to a delayed viral decline.
Many patients are deemed as non-responsive to GCV therapy if by day 21 the viral load is
not declining or has not declined to an undetectable level [29]. In light of this, drug resistance
may be suspected and in some patients switching to other drugs such as Foscarnet or Cidofovir
would be considered. However, our mathematical model predicts that at least in some of these
patients, specifically patients with no drug resistance mutations, the observed Rebound (RB)
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group is a ‘slowed down’ version of the Hump kinetic pattern. Thus, maintaining GCV therapy
at full dose in these RB patients may be warranted since CMV loads could start declining
again, perhaps even to undetectable levels over the following 28 days. This prediction is sup-
ported by the observation in the VICTOR study that patients who had not cleared CMV from
their blood by day 21 and who were in the RB kinetic profile became PCR-negative in plasma
by day 49 or 84 [29].
An important limitation of our study is the lack of pre-treatment viral load data and hence it
is not possible to verify that viremia was at steady state at the initiation of therapy, as assumed
in the model. Indeed it has been previously shown by us [41] in stem cell transplant patients
that in some patients, therapy is initiated when CMV is rapidly increasing thus potentially
altering the kinetic pattern after initiation of therapy. However, this occurred in patients being
treated pre-emptively with viral loads less than 10,000 genomes per ml of blood, while, in con-
trast, the patients in the VICTOR study had much higher viral loads when ganciclovir treat-
ment was initiated. Moreover, the stem cell transplant patients with a pre-treatment rapid viral
load increase showed a continued increase at the beginning of therapy [41], while here we did
not observe any patient in the present study with an increase in viral load between days 0 to 3.
At present, our modeling effort focused on patients with mono-genotypic infection (as
judged by glycoprotein B typing) however, we have validated our kinetic pattern classification
(and model) in patients with multi-genotypic infections [42,43] and again, observed all 4 viral
decay patterns. Unfortunately, because of the distribution of different combinations of gB
genotypes in the mixed-genotype infected patients, the sub-sets were too small for us to under-
take a full analysis.
In conclusion, the central tenet of our CMV-GCV model is the negative feedback loop
between CMV replication and GCV activation, which is mediated through the dynamics of
the UL97 kinase. This allows a more accurate description of CMV kinetics following antiviral
therapy. We expect these insights to contribute to understanding and optimizing the effective
clinical management of CMV with existing and new antiviral compounds in advanced clinical
development.
Materials and methods
Patients and viral load measurement
The VICTOR study included patients who were solid organ recipients with cytomegalovirus
(CMV) disease at the time of enrolment. It was a randomized, open-label, parallel-group,
active drug-controlled, multi-center non-inferiority trial in adult solid organ transplant recipi-
ents with CMV disease (ClinicalTrials.gov NCT00431353) and was conducted in accordance
with the Declaration of Helsinki, good clinical practice guidelines and applicable local regula-
tory requirements as previously reported [29]. This 2-arm study evaluated the efficacy and
safety of 2 forms of ganciclovir (GCV): oral valganciclovir (Valcyte) compared with intrave-
nous ganciclovir for the treatment of CMV disease. Eligible patients were randomized to
receive either 1) valganciclovir 900 mg po bid or 2) Ganciclovir 5mg/kg iv bid for 21 days, and
then both arms continued with maintenance valganciclovir [dose 900 mg/day until day 49]
with all dosages adjusted for renal function [29]. For the purposes of our kinetic analysis, we
included only the 113 patients in whom a single CMV gB genotype infection was present. As a
validation step we tested our classification criteria on an additional 89 patients with a mixed
CMV gB genotype infection. Patients with any genotypic mutations possibly associated with
resistance to GCV, as measured by a nested PCR assay covering (UL97 and UL54) all known
resistance mutations to GCV [44], tested at all visits during the study, were excluded from the
analysis.
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Whole blood (WB) CMV viral loads were measured at days 0, 3, 7, 14 and 21 by a CMV
genotype specific real-time PCR assay as previously described [45]. This in-house assay was
validated to have better inter-assay variability (0.1–0.15 log) than commercial assays for CMV
quantification and a high sensitivity (LLD = 50 copies/ml, LLQ = 500 copies/ml) [45]. Patients
that were missing viral load data between days 0 and 21 were omitted from the analysis. Conse-
quently, we analyzed viral kinetics in a total of 92 patients with a single genotype infection in
the initial analysis, and gB1 viral kinetics in an additional 72 patients a mixed-genotype infec-
tion in the validation step. There was no difference in viral kinetics between the 2 study arms
and thus we analyzed the cohort as a whole [29].
Ethical statement
The sub-study described in this paper was approved by the Norwegian Ethics Committee, Sec-
tion for Health Region South-East (IRB number: S-04011). All data was anonymized prior to
analysis. All patients had given written informed consent.
Viral kinetics pattern classification
The four kinetic profiles were assigned based upon the viral kinetic pattern during the first 21
days of therapy. A patient was classified as having a Biphasic (BP) profile if the first phase
(days 0–3) showed a rapid decline, larger than 0.5 log, and then a second phase (days 3–21)
with a slower continuous decline. A Hump (HM) profile was defined by a first phase (days
0–3) with a rapid decline, larger than 0.5 log, followed by an intermediate shoulder or hump
phase (at days 3–7, 7–14 or 3–14) with no viral decline (less than 0.15 log decline, where 0.15
log is the inter-assay variability of the assay used to quantify CMV load) or with a viral load
increase, but nevertheless a later second phase decline (days 7–21 or 14–21). A Rebound (RB)
profile was defined by a rapid viral load decline in the first phase (days 0–3), larger than 0.5
log, followed by a continuous increase in viral load at days 3–21 or 7–21, instead of a second
phase decline. A Delay (DL) profile was defined by a slow first phase decline (days 0–3) of less
than 0.5 logs, followed by a decline at days 3–21. It should be noted that we made no a priori
hypothesis related to the number or nature of the kinetic patterns, but rather selected the crite-
ria that minimized the number of kinetic patterns.
Statistical analysis
Statistical analyses were done using SPSS. Correlations were tested for statistical significance
using the non-parametric Spearman test. The Fischer exact test was used to test statistical sig-
nificance in differences of proportions between groups. The non-parametric Mann-Whitney
test was used to determine if differences in distribution of parameters between groups of
patients were statistically significant. The significance threshold was set at 0.05 except where
multiple comparisons were performed in which the threshold was reduced accordingly. In the
text, we have only highlighted significant differences where the p-values fall below a 0.0017
threshold.
Viral dynamics model of the GCV-CMV interaction
CMV transcription occurs in three stages: early, intermediate and late with DNA replication
occurring after early transcription and via the production of a concatemeric structure that is
then cleaved and packaged into new virions [3]. GCV triphosphate (GCVTP) interrupts this
process by inhibiting viral DNA replication. We assume that this occurs at the lengthening
stage: the drug inhibits lengthening of the viral DNA so that the precursor DNA for packaging
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is ultimately not produced. Studies have shown that GCV triphosphate levels are at least
100-fold greater in CMV-infected cells than in non-infected cells [13]. In order for GCV in the
cells to be transformed into GCVTP it has to be initially phosphorylated by the CMV kinase
UL97. Since UL97 is transcribed as an early-late gene, which likely requires DNA replication
for maximum expression, we hypothesized that UL97 levels change according to the change in
intracellular replication levels. Therefore, changing replication levels would result in changes
of GCVTP levels, which ultimately would change the blocking efficacy of ganciclovir.
Thus, based upon the above assumptions, we have developed a viral dynamic model that
combines the intracellular interaction between GCV and UL97 together with the blocking
effect of GCV on CMV. Briefly, G0 is the intracellular GCV drug concentration. D1 represents
the linear/circular/concatemeric forms of viral DNA, and D2 represents the cleaved and pack-
aged viral DNA. UL97 phosphorylates GCV (G0) to produce a mono-phosphorylated form of
the drug (G1) which is rapidly metabolized to the active tri-phosphorylated form of the drug
(G3) by cellular kinases. This active form of the drug then acts primarily on the replication of
D1 to inhibit the prolongation of the linear DNA, formation of circular DNA and subsequent
packaging of DNA for new virions. Since D1 is assumed to be the template for UL97 transcripts
and hence the UL97 protein, this produces a negative-feedback loop causing the eventual
reduction in both D1 and subsequently UL97 (Fig 2b).
In the absence of adequate quantities of UL97, the drug, which continues to enter the cell
(as patients are undergoing continued dosing twice a day) does not get phosphorylated effi-
ciently and so drug efficacy is reduced. This means that the viral content in the cell in the form
of D1 and D2 eventually begins to rise, peak and subsequently plateau at new steady state levels.
In addition, since V originates from D2, V also declines and then rises albeit, more slowly.
Once UL97 is restored to large enough quantities due to continued viral replication, the drug
is again phosphorylated, can act as an inhibitor of DNA synthesis, and the cycle continues.
This could manifest as a transient rise in intracellular (cell-associated) DNA content and gives
rise to oscillatory behavior.
The differential equations that follow from above assumptions (see schematic representa-
tion in Fig 2b) are as follows.
dT=dt ¼ s   dT   bTV
dI=dt ¼ bTV   dI
dU=dt ¼ gD1   duU
dG3=dt ¼ kUG0   dGG3
dD1=dt ¼ ð1   εÞr1   r1D1
dD2=dt ¼ r1D1   r2D2
dV=dt ¼ Pfracr2D2I   cVV
where Pfrac = q.
The model contains seven variables that represent: uninfected cells (T), infected cells (I),
intracellular UL97 enzyme (U), the intracellular triphosphate form of GCV (G3), the linear form
of the viral DNA which becomes elongated for eventual cleavage into component viral parts,
(D1), assembled capsid forms in which the scaffolding has been removed and replaced with viral
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DNA (D2), and consequently released to the circulation as free virus (V). Uninfected cells are
produced at a rate s, die at a rate d, and become infected with rate constant β. Infected cells are
lost at a rate δ. UL97 is produced at rate g from the linear DNA form (D1) and is lost at rate du.
G3 is produces at rate k as a first order linear interaction of UL97 and the non-phosphorylated
form of GCV (G0) and lost at rate dG. The linear DNA form (D1) replicates at rate r1 and is trans-
formed at rate ρ1 to produce D2 that is lost at rate ρ2. A fraction Pfrac (q) (/ml) of this cleaved
virus (D2) becomes free virus with a clearance rate of cV. The variables in the model represent
populations expressed as concentration per milliliter of blood and specifically, the units for cell
populations are cells/ml while viral population units are virions/ml. Both the viral enzyme and
the drug population units are molecules/cell/ml. It is assumed that mixing in each compartment
is instantaneous—that is, intracellular and extracellular diffusion are assumed to be fast on the
scale of an individual cell. Parameter rate constants are summarized follows (Table 3).
To represent the antiviral effect of GCV we introduce a parameter, ε, to block the produc-
tion rate of D1 where the blocking effectiveness depends on the availability of GCV by:
ε ¼ G3
h=ðy
h
þ G3
hÞ:
This equation utilizes the Hill function: the Hill coefficient, h, represents the steepness of
the Hill saturation function and defines the sensitivity of the blocking effectiveness to changes
in drug level via cooperativity of drug binding.
The total whole blood viral load is then calculated as:
WB ¼ ðD1 þ D2ÞI þ V
and this variable is fitted to the measured viral load.
All modeling was performed with the Berkeley Madonna package and fitting performed
using the Runge-Kutta4 method.
Data fitting
Considering that our model is novel and has 7 variables (only one of which is measurable) and
15 parameters which are very difficult to measure experimentally in vivo (and outside of the
scope of this particular work), we explored different parameter sets or landscapes in order to
identify which of the parameters, or sets of parameters, were the most influential in giving rise
to one kinetic profile or another. We systematically examined the sensitivity of each parameter
Table 3. Units of variables and parameters.
Variable Units Parameters Units
T cells/ml s cells/ml/day
I cells/ml β ml/virion/day
U molecules/cell/ml D 1/day
G3 molecules/cell/ml δ 1/day
D1 virions/cell/ml g molecules/virion/day
D2 virions/cell/ml du 1/day
V virions/ml k (ml/molecule)*(cell/day)
dg 1/day
R1 virions/cell/ml/day
ρ1 1/day
ρ2 1/day
cV 1/day
https://doi.org/10.1371/journal.ppat.1006299.t003
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while keeping the rest constant to primarily assess the effect that each had on the system. This
was done by data fitting numerically using the Runge-Kutta iterative method. We also investi-
gated potential relationships between the parameters themselves. Once we had established
which parameters were most sensitive, we sought to minimize the number of free-fit parame-
ters in order to be more robust in our analysis. We subsequently investigated which parame-
ters must remain constant in order to obtain all 4 kinetic profiles. We set these selected
parameters at constant values that were based on a quasi steady state analysis and available bio-
logical information with previously generated estimates [46]. We used the relationships
observed between the parameters from the quasi steady state analysis to characterize each
parameter. By replacing each parameter with a scaled version, we figured out if each repre-
sented a combination of other parameters or non-observed variables. To try to understand
exactly why we see the unique profiles, we examined the effects of changing each parameter,
alone and in tandem with others for each profile. We found that some parameters dictate the
profile patterns while others simply promote them. Consequently, five parameters were identi-
fied that produce the differences between one kinetic profile and another: ρ1, ρ2, h, δ and du.
The values of the other parameters were fixed in the simulations and in the data fitting to:
s = 106; d = 0.1; k = 105; g = 0.01; G0 = 0.06; dG = 1; θ = 103; r1 = 1000, c = 0.26; Pfrac = 0.09. We
tested a large range of other values for the fixed parameters and the qualitative results reported
here, in relation to the free parameter values, did not change.
Supporting information
S1 Fig. Simulations of the GCV-CMV model showing the kinetics of cellular level variables:
Whole blood viral load (WB, black curves) and infected cells (I, green dashed curves), and
intracellular level variables: UL97 kinase (U, blue curves), active tri-phosphorylated form
of ganciclovir (G3, red dots) and linear/circular/concatemeric forms of viral DNA (D1, blue
dashed curves). Each simulation is fitted to viral load data (blue triangles) from a representa-
tive patient from each kinetic profile, thus depicting the differences in the behavior of these
variables between the four kinetic profiles (HM (panel A), BP (panel B), DL (panel C) and RB
(panel D)).
(TIF)
S2 Fig. A histogram of the distribution of the five parameters (ρ1, ρ2, h, δ and du) that were
free to vary in the fitting of the viral kinetic data of all patients across the different kinetic
profiles (HM (panel A), BP (panel B), DL (panel C) and RB (panel D)).
(TIF)
S3 Fig. Effect of dose changes in GCV is simulated for each kinetic profile (HM, BP, DL
and RB) by changes in the drug effectiveness, ε, in blocking CMV DNA replication. G0 was
modified to mimic a change in drug dose that mimicked drug efficacies that equated to ε at
80% (black solid line), 90% (mean—dashed black line) and 95% (dotted black line) for each
profile. The mean data is also shown for each profile. The limit of detection (LOD) of the viral
load (400 copies/ml) is shown by the horizontal green line.
(TIF)
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